GermanyGermany

Micromet’ s blitumab meets study goals

15.06.2010

Martinsried/Bethesda – Micromets bifunctional monoclonal antibody drug blinatumomab (MT103) has met its study goals in two independent clinical trails. In a Phase I dose escalation study in 52 adult patients with relapsed non-Hodgkin's lymphoma (NHL), the BITE antibody which activates T- killer cells against tumour cells, achieved an objective response rate of 100% (8 of 8 patients) at a once daily dosage of 60µg/sqm. The median response duration was 21 months. However, in a sub-group of patients with an identified prognostic factor, Blinatumomab induced neurologic events that led to study discontinuation. This was avoided when starting with a low dosage of 15µg/mg ("step-dose approach"), with no grade 3 or higher neurological events occurring and five objective responses being achieved among the six patients treated with MT103. In a Phase 2 trial in adult patients with minimal residual disease (MRD) in positive acute lymphoblastic leukemia (ALL), Blinatumomab achieved 1st primary endpoint of MRD response. Of 20 evaluable patients, who received 15µg/sqm, 80% (16 out of 20) achieved a complete MRD response. Key secondary endpoints included time to hematological relapse, time to molecular relapse and overall incidence and severity of adverse events. Based on the results reported to date in ALL, Micromet plans to initiate a pivotal, non-randomized, multi-center trial intended to confirm the efficacy and safety of blinatumomab in adult patients with B precursor ALL with minimal residual disease after treatment with front-line chemotherapy. Patients will receive 15 micrograms per meter squared per day of blinatumomab for 28 days followed by two weeks off therapy over a six week treatment cycle. The primary endpoint of the study is MRD response as assessed by PCR analysis. The key secondary endpoint is time to hematological relapse (for non-transplanted patients). The Company currently plans to enroll up to 130 evaluable patients at approximately 70 leading cancer centers in Europe and the U.S.


Politics / Law

06.03.2012

London – The European Medicines Agency (EMA) calls it “the biggest change to the legal framework since the establishment of the Agency in 1995.” This year, the EU drug regulators are preparing new so-called pharmacovigilance...

Clinical Trial

06.03.2012

Norway’s Algeta ASA (Oslo) has updated its Phase III survival analysis of Alpharadin in patients with castration-resistant prostate cancer and bone metastases. The analysis showed an increase of 3.6 months in median overall...

Clinical Trial

06.03.2012

Genticel S.A. (Toulouse) has completed enrolment in its Phase Ib study of a lyophilised version of the world’s very first therapeutic vaccine ProCervix, which inhibits infection with the cancer-causing Human Papilloma Virus. The...

Clinical Trial

06.03.2012

The share value of French specialist for cardiometabolic diseases Genfit S.A. (Loos/Lille) took a jump after the company announced its candidate drug GFT505 had met all efficacy endpoints in a pilot Phase II study involving 22...

Clinical Trial

06.03.2012

The US Food and Drug Administration (FDA) has granted a Biologics License Application (BLA) to the HER2 dimerisation inhibitor pertuzumab developed by Roche (Basel) for previously untreated HER2­-positive metastatic breast...

Politics / Law

06.03.2012

A For years, the world’s major patent offices – including the EPO, USPTO and JPO – have been collaborating in the Patent Prosecution Highway (PPH) programme. Under the PPH, an applicant whose claims have been allowed in one...

BioFunding

06.03.2012

Berlin/Dublin – Two EU initiatives are seeking to better predict response to cancer treatments. Researchers from the a6m RESPONSIFY Project will develop biomarker-based breast cancer prognosis tests that could be used to predict...

BioFunding

06.03.2012

Bremen/Brussels – European researchers kicked-off the MicroB3 (Bio­diversity, Bioinformatics, Biotechnology) project in February. Thanks to a a9m EU fund, the 32 groups involved will create a unique bioinformatic resource that...

BioFunding

06.03.2012

A Brussels – The European Commission is boosting its investments and policy activities to foster sustainability. “Europe needs to make the transition to a post-petroleum economy,” said Máire Geoghegan-Quinn in Brussels. In...

Politics / Law

06.03.2012

Brussels – In February, I heard of a slightly mad and very worrying trend in decisions handed down by the Court of Justice of the European Union (CJEU) with regard to IP issues handed up from the national level for clarification....

Displaying results 11 to 20 out of 1983

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive/browse/1/article/micromet-s-blitumab-meets-study-goals.html

Print Magazine

Event Video

All videos

Events

All Events

Stock list

All quotes

TOP

  • MOLOGEN7.65 EUR18.42%
  • BB BIOTECH150.50 EUR5.10%
  • CO.DON2.69 EUR4.26%

FLOP

  • 4SC0.80 EUR-8.05%
  • CYTOS0.16 CHF-5.88%
  • WILEX2.15 EUR-4.44%

TOP

  • BIOFRONTERA2.85 EUR27.2%
  • MOLOGEN7.65 EUR3.4%
  • HBM85.50 CHF3.1%

FLOP

  • PAION2.20 EUR-32.3%
  • 4SC0.80 EUR-29.8%
  • CYTOS0.16 CHF-23.8%

TOP

  • SANTHERA81.90 CHF2267.1%
  • CO.DON2.69 EUR195.6%
  • PAION2.20 EUR155.8%

FLOP

  • CYTOS0.16 CHF-95.9%
  • 4SC0.80 EUR-54.0%
  • THERAMETRICS0.07 CHF-46.2%

No liability assumed, Date: 21.10.2014


Current issue

All issues

Product of the week

Products